Museum of Science & History (MoSH) Exhibit
in Memphis, TN Runs Until
May 6, 2023
TORONTO and DALLAS, Feb. 8, 2023
/CNW/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) –
Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") –
a commercial-stage medical technology company – announced that its
investigational AI technology is being featured in a museum exhibit
entitled "Artificial Intelligence: Your Mind & The Machine,"
which is open now through May 6, 2023
at the Museum of Science & History (MoSH) in Memphis, TN.
Jeremy Sobotta, Perimeter's Chief
Executive Officer stated, "We're excited and honored to be included
in the MoSH exhibit that covers a wide variety ways AI is being
used now and in the future. Breast surgeons at West Cancer Center
& Research Institute in Memphis were among the first healthcare
leaders to participate in our ongoing clinical trial evaluating
Perimeter's next-generation ultra-high resolution optical imaging
technology using AI. Our goal is to harness the power of machine
learning and AI to help surgeons quickly visualize microscopic
tissue structures in real time so they can make more informed
decisions in the operating room in the hopes of reducing
re-operations and improving outcomes for cancer patients."
Mr. Sobotta continued, "Importantly, our next-gen AI is built
upon Perimeter's own technology platform that includes our
commercially launched S-Series OCT imaging system along with an
extensive proprietary data set, or visual library. As we develop
and commercialize this game-changing technology, we have the
benefit of strategic guidance from AI industry leaders, such as
Anantha Kancherla of Meta, who
sits on the Perimeter Board of Directors. Looking even further
ahead, we see the potential to leverage our AI knowledge in other
healthcare applications beyond cancer surgery."
More information about the MoSH exhibit can be found here.
About Perimeter Medical Imaging AI, Inc.
Based in
Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging
AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a
medical technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation
artificial intelligence technology that is currently being
evaluated in a pivotal clinical trial, with support from a grant of
up to US$7.4 million awarded by the
Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a
reference to the pink ribbons used during Breast Cancer Awareness
Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains
statements that constitute "forward-looking information" within the
meaning of applicable Canadian securities legislation. In this news
release, words such as "may," "would," "could," "will," "likely,"
"believe," "expect," "anticipate," "intend," "plan," "estimate,"
and similar words and the negative form thereof are used to
identify forward-looking statements. Forward-looking information
may relate to management's future outlook and anticipated events or
results and may include statements or information regarding the
future financial position, business strategy and strategic goals,
competitive conditions, research and development activities,
projected costs and capital expenditures, research and clinical
testing outcomes, taxes and plans and objectives of, or involving,
Perimeter. Without limitation, information regarding the potential
benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and
Perimeter ImgAssist and Perimeter's business focus are
forward-looking information. Forward-looking statements should not
be read as guarantees of future performance or results, and will
not necessarily be accurate indications of whether, or the times at
or by which, any particular result will be achieved. No assurance
can be given that any events anticipated by the forward-looking
information will transpire or occur. Forward-looking information is
based on information available at the time and/or management's
good-faith belief with respect to future events and are subject to
known or unknown risks, uncertainties, assumptions, and other
unpredictable factors, many of which are beyond Perimeter's
control. Such forward-looking statements reflect Perimeter's
current view with respect to future events, but are inherently
subject to significant medical, scientific, business, economic,
competitive, political, and social uncertainties and contingencies.
In making forward-looking statements, Perimeter may make various
material assumptions, including but not limited to (i) the accuracy
of Perimeter's financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter's Management Discussion and Analysis for the year
ended December 31, 2021, which is
available on Perimeter's SEDAR profile at www.sedar.com, and could
cause actual events or results to differ materially from those
projected in any forward-looking statements. Perimeter does not
intend, nor does Perimeter undertake any obligation, to update or
revise any forward-looking information contained in this news
release to reflect subsequent information, events, or circumstances
or otherwise, except if required by applicable laws.
CONTACT:
Jeremy
Sobotta
Chief Executive
Officer
Perimeter Medical Imaging AI,
Inc.
Toll-free: 888-988-7465 (PINK)
Jodi
Regts
Perimeter Medical Imaging AI,
Inc.
Direct:
469-743-1834
Investors:
investors@perimetermed.com
Media: media@perimetermed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-its-proprietary-ai-technology-is-featured-in-an-interactive-museum-exhibit-on-artificial-intelligence-301741482.html
SOURCE Perimeter Medical Imaging, Inc.
